New Project (1)

Day: December 6, 2022

Calgon Carbon Reactivation Study Shows Removal and Destruction of PFAS

Peer-reviewed journal article details Calgon Carbon study findings Pittsburgh, PA, Dec. 06, 2022 (GLOBE NEWSWIRE) — A new study by Calgon Carbon Corporation (“Calgon Carbon”), a wholly owned subsidiary of Kuraray Co., Ltd. (TYO: 3405) (“Kuraray”), has provided a definitive response to a persistent question about the fate of PFAS during reactivation of activated carbon. Reactivation is […]

Read More »

Graid Technology and Liqid Announce Accelerated Data Protection for the World’s Fastest NVMe Flash

SupremeRAID™ SR-1010 delivers best-in-class data protection, maximum flexibility, and even greater performance from Liqid’s Honey Badger NVMe storage devices SANTA CLARA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) — Graid Technology, the multi-award-winning data protection provider and developer of the only RAID card to deliver the full performance capability of NVMe SSDs, and Liqid, a leading […]

Read More »

Nucleus Software Implements Digital Lending Solution to Bank of Sydney, Empowering a Shift Towards Digital Customer Experience

The solution allows the bank to deliver faster credit decisions and automate workflows, enhancing business agility and productivity. SYDNEY, Dec. 06, 2022 (GLOBE NEWSWIRE) — Nucleus Software transforms Bank of Sydney towards digital customer experience with FinnOne neo™ solution. Bank of Sydney is an organization committed to providing genuine value for its people, customers, communities, […]

Read More »

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer’s disease (AD) patients TB006 also demonstrated improvements in PET and MR imaging, consistent with dissolution of toxic amyloid plaque shown in preclinical studies Ongoing open-label extension study with more than 100 […]

Read More »

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, announced today its participation in a $52 million Series C extension financing round in portfolio company […]

Read More »

 Search

 Recent Post

 Calendar

December 2022
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031